drugset
drugset / Trial / NCT02694354

Investigation of Single Rising Doses of BI 685509

NCT02694354 ↗

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising oral doses of BI 685509

Timeline

Start
2016-03
Primary completion
2016-04
Completion
2016-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Avenciguat Small molecule 1 mg Oral
Subject Avenciguat Small molecule 2.5 mg Oral
Subject Avenciguat Small molecule 5 mg Oral

Indications

No indication recorded.